Literature DB >> 10571622

Trends in repeat prostatectomy after surgery for benign prostate disease: application of record linkage to healthcare outcomes.

J B Semmens1, Z S Wisniewski, A J Bass, C D Holman, I L Rouse.   

Abstract

OBJECTIVE: To compare the risk of repeat prostatectomy for benign prostatic hyperplasia (BPH) in a population-based cohort of 19 598 men in Western Australia treated by transurethral resection of the prostate (TURP) or open prostatectomy over a 16-year period. PATIENTS AND METHODS: The Western Australian Health Services Research Linked Database was used to extract all hospital morbidity data, death records and prostate cancer registrations for men who had prostate surgery for BPH in 1980-95. The cumulative incidence of first repeat prostatectomy calculated using the actuarial life-table and incidence-rate ratios of the first repeat prostatectomy, comparing TURP and open prostatectomy, were obtained using Cox regression.
RESULTS: The cases comprised 18 464 TURPs and 1134 open prostatectomies, from which there were 1095 subsequent repeat prostatectomies. After adjustment for calendar time, age and admission type, the incidence rate of the first repeat prostatectomy was up to 2.30 times higher (95% confidence interval, 1.62-3.27) after initial TURP than for initial open prostatectomy. The absolute risks at 8 years for TURP was 6.6%, and was 3.3% for open prostatectomy.
CONCLUSION: The absolute risk of a repeat prostatectomy for TURP and open prostatectomy were consistent with the best reported international experience. There was evidence that the risk in 1990-95 had declined compared with earlier periods, despite a shift towards more closed procedures. The differential risks of repeat prostatectomy should be explained to patients and considered in the development of clinical guidelines, notwithstanding the advantages of TURP over open prostatectomy in terms of surgical morbidity and cost.

Entities:  

Mesh:

Year:  1999        PMID: 10571622     DOI: 10.1046/j.1464-410x.1999.00359.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  4 in total

1.  Cost analysis of fixed-dose combination of dutasteride and tamsulosin compared with concomitant dutasteride and tamsulosin monotherapy in patients with benign prostatic hyperplasia in Canada.

Authors:  Amyn Sayani; Afisi Ismaila; Anna Walker; John Posnett; Bruno Laroche; J Curtis Nickel; Zhen Su
Journal:  Can Urol Assoc J       Date:  2014 Jan-Feb       Impact factor: 1.862

2.  Cost-effectiveness of dutasteride-tamsulosin combination therapy for the treatment of symptomatic benign prostatic hyperplasia: A Canadian model based on the CombAT trial.

Authors:  Afisi Ismaila; Anna Walker; Amyn Sayani; Bruno Laroche; J Curtis Nickel; John Posnett; Zhen Su
Journal:  Can Urol Assoc J       Date:  2013-06-12       Impact factor: 1.862

Review 3.  Changing therapeutic regimens in benign prostatic hyperplasia. Clinical and economic considerations.

Authors:  H J Stoevelaar; J McDonnell
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

4.  Internal optical urethrotomy is the treatment of choice in stenosis of the bladder neck after open prostate adenectomy.

Authors:  Tomasz Borkowski; Jędrzej Michalec; Boleslaw Kuzaka; Andrzej Borkowski; Piotr Radziszewski
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2019-02-05       Impact factor: 1.195

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.